Apnimed, backed by Japanese drugmaker Shionogi, files IPO to raise capital for Phase 3 trial of oral sleep apnea therapy, targeting a…
AstraZeneca stock drops following unexpected failure of a heart disease drug trial.
Galderma shares sank after the FDA rejected its Botox rival Relfydess, delaying U.S. market entry and strengthening AbbVie's grip on the aesthetics…
Swiss President Keller-Sutter's meeting with USTR Greer aims to resolve US-Swiss tariff tensions that threaten Swiss exports in pharma and machinery, with…
Novo Holdings launches Europe-wide obesity drug incubators to strengthen Novo Nordisk's weight-loss R&D and challenge rivals in the booming GLP-1 market.
Apotex's $932 million IPO, priced at the top of the range, reflects strong demand for Canadian pharmaceutical stocks and could boost the…
Apotex's IPO is poised to price at the high end of its range, underscoring strong investor appetite for the Canadian generic drugmaker…
Novo Nordisk’s blockbuster drug exports drive Denmark’s GDP growth above eurozone levels, per Danske Bank, fueling a trade surplus and potentially strengthening…
Scientists are tracking Ebola survivors in remote mountains to harvest antibodies for a cure, offering new hope against the virus and potential…
Apotex Health's planned C$1.2 billion Toronto IPO underscores strong demand for Canadian healthcare equities, with potential to lift the S&P/TSX Composite Index…
Big Caring, Malaysia’s top pharma retailer, targets a $750 million IPO, marking a major test for equity capital markets in the region.
Apotex Health's IPO on the TSX signals a thaw in Canadian public markets, potentially reviving equity issuance and investor sentiment.